Newsroom
Featured News
Image
People & Impact
Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.
Patient Voices
Explore Yajaira's journey with severe hypertriglyceridemia (sHTG), including the risks of high triglycerides, pancreatitis, and the importance of early awareness.
Image
Patient Voices
March marks Amyloidosis Awareness Month. We sat down with Charles, an 88-year-old retired cardiologist from Massachusetts, who shared what it’s like to diagnose and treat heart disease for decades and then face a diagnosis himself. His experience with transthyretin amyloid cardiomyopathy (ATTR-CM) offers a unique perspective on this underrecognized condition.
Image
Defining Moments
2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company. Now, Ionis is poised for another transformative year - at JPM 2026 we shared highlights from the past year and outlined key anticipated milestones.
Image
Recent posts
Image
Patient Voices
Living with an Invisible Illness: Yajaira’s Journey with Severe Hypertriglyceridemia (sHTG)
Image
People & Impact
Our 2025 Corporate Responsibility Report: Building Momentum for Better Futures
Image
Patient Voices
From Treating ATTR-CM to Living with It: A Conversation with a Cardiologist
Image
Defining Moments
Ionis JPM 2026 Takeaways: Breakthrough Therapies Driving Accelerating Growth
Image
Patient Voices
Behind the Mystery of Angelman Syndrome: A Journey of Resilience and Strength
Image
Patient Voices
Meet Rick: Navigating Life with Familial Chylomicronemia Syndrome (FCS)
Image
Image
People & Impact
Ionis CEO Brett Monia, Ph.D Receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Image
Sign up for investor news alerts
For the latest on Ionis investor news.